More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Nocodazole [31430-18-9]
Chemical Structure
Chemical Structure
Chemical Structure

Nocodazole [31430-18-9]

Research Use Only
AG-CR1-0019
AdipoGen Life Sciences
CAS Number31430-18-9
DownloadDatasheet
DownloadMSDS
Product group Chemicals
Estimated Purity>98% (NMR)
Molecular Weight301.3
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Nocodazole [31430-18-9]
  • Delivery Days Customer
    10
  • CAS Number
    31430-18-9
  • Certification
    Research Use Only
  • Estimated Purity
    >98% (NMR)
  • Hazard Information
    Non-hazardous,Warning
  • Molecular Formula
    C14H11N3O3S
  • Molecular Weight
    301.3
  • Scientific Description
    Chemical. CAS: 31430-18-9. Formula: C14H11N3O3S. MW: 301.3. Microtubule inhibitor. Antitumor compound. Mitosis inhibitor. Arrests the cell cycle at G2/M phase. Promotes tubulin depolymerization. Induces fragmentation of the Golgi complex. Inhibits the T cell antigen receptor. Stimulates the intrinsic GTPase activity of tubulin. Activates the JNK/SAPK signaling pathway. Apoptosis inducer. Autophagy inhibition through prevention of autophagosome-lysosome fusion. - Microtubule inhibitor [1, 2, 4]. Antitumor compound [1, 2]. Mitosis inhibitor [3]. Arrests the cell cycle at G2/M phase [9]. Promotes tubulin depolymerization [4]. Induces fragmentation of the Golgi complex [5]. Inhibits the T cell antigen receptor [6]. Stimulates the intrinsic GTPase activity of tubulin [7]. Activates the JNK/SAPK signaling pathway [8]. Apoptosis inducer [10, 11]. Autophagy inhibition through prevention of autophagosome-lysosome fusion.
  • SMILES
    COC(=O)NC1=NC2=CC=C(C=C2N1)C(=O)C1=CC=CS1
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    12352200

References

  • R17934-NSC 238159: a new antitumor drug--I. Effect on experimental tumors and factors influencing effectiveness: G. Atassi and H.J. Tagnon; Eur. J. Cancer 11, 599 (1975)
  • R17934-NSC238159: a new antitumor drug--II. Effect on mitotic cycle of L1210 leukemia cells in vivo and synergism with cytosine arabinoside (NSC63878): G. Atassi, et al.; Eur. J. Cancer 11, 609 (1975)
  • Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis; M.A. Jordan, et al.; J. Cell Sci. 102, 401 (1992)
  • Nanomolar concentrations of nocodazole alter microtubule dynamic instability in vivo and in vitro: R.J. Vasquez, et al.; Mol. Biol. Cell 8, 973 (1997)
  • Recycling of golgi-resident glycosyltransferases through the ER reveals a novel pathway and provides an explanation for nocodazole-induced Golgi scattering: B. Storrie, et al.; J. Cell Biol. 143, 1505 (1998)
  • Nocodazole inhibits signal transduction by the T cell antigen receptor: R.D. Huby, et al.; J. Biol. Chem. 273, 12024 (1998)
  • Studies on the nocodazole-induced GTPase activity of tubulin: M.R. Mejillano, et al.; Arch. Biochem. Biophys. 336, 130 (1996)
  • Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways: T.H. Wang, et al.; J. Biol. Chem. 273, 4928 (1998)
  • Raf-1/MEK/MAPK pathway is necessary for the G2/M transition induced by nocodazole: C. Hayne, et al.; J. Biol. Chem. 275, 31876 (2000)
  • Apoptosis induced by microtubule disrupting drugs in normal murine thymocytes in vitro: V. Bumbasirevic, et al.; Scanning Microsc. 9, 509 (1995)